DOCSLIB.ORG

Search Results

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Evidence Services | library.nhs.uk Search Results Table of Contents Search History ........................................................................................................................................................... page 7 1. [Influence of boric acid on strains of the genus Candida]. .................................................................................... page 8 2. Boric acid treatment of vulvovaginal candidiasis. ................................................................................................. page 8 3. Diaper dermatitis: current concepts. ...................................................................................................................... page 8 4. Treatment of vulvovaginal candidiasis with boric acid powder. ............................................................................ page 9 5. Current therapy of vulvovaginitis. ......................................................................................................................... page 9 6. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. ....................................... page 10 7. Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata. ........................... page 10 8. Boric acid vaginal suppositories. ......................................................................................................................... page 11 9. Biotypes of oral Candida albicans isolates in human immunodeficiency virus-infected patients from diverse geographic locations. ................................................................................................................................................ page 11 10. Oral Candida albicans biotypes in Chinese patients with and without oral candidosis. .................................... page 12 11. Chronic fungal vaginitis: the value of cultures. ................................................................................................. page 12 12. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. ................................... page 13 13. Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS. ................ page 13 14. Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. .......................................................................................................................................................................... page 14 15. Terconazole cream for non-Candida albicans fungal vaginitis: results of a retrospective analysis. .................. page 14 16. Phenotypic characterisation of Candida albicans isolated from chronic hyperplastic candidosis. .................... page 15 17. Biotypes of oral Candida albicans isolated from AIDS patients and HIV-free subjects in Thailand. ............... page 16 18. Candida albicans strain differentiation in complete denture wearers. ............................................................... page 16 19. Candida lusitaniae as an unusual cause of recurrent vaginitis and its successful treatment with intravaginal boric acid. .......................................................................................................................................................................... page 17 20. Boric acid susceptibility testing of non-C. albicans Candida and Saccharomyces cerevisiae: comparison of three methods. ................................................................................................................................................................... page 17 21. Vulvovaginal trichosporonosis. .......................................................................................................................... page 18 22. Phenotypic diversity of oral C. albicans isolated on single and sequential visits in an HIV-infected Chinese cohort. .................................................................................................................................................................................. page 19 23. Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: a systematic review. .................................................................................................................................................................................. page 19 24. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. ........................ page 20 25. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival Candida albicans isolates in HIV infection. .......................................................................................................................................................... page 21 26. Biotypes and randomly amplified polymorphic DNA (RAPD) profiles of subgingival Candida albicans isolates in HIV infection ........................................................................................................................................................... page 22 27. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates ................................................................................................................. page 23 28. In vitro activity of bergamot natural essence and furocoumarin-free and distilled extracts, and their associations with boric acid, against clinical yeast isolates. ................................................................................................................ page 24 29. Vaginal Candida parapsilosis: pathogen or bystander? ...................................................................................... page 24 30. Vaginal Candida parapsilosis: Pathogen or bystander? ...................................................................................... page 25 Page 1 Evidence Services | library.nhs.uk 31. Recurrent vulvovaginal candidiasis ................................................................................................................... page 26 32. Recurrent vulvovaginal candidiasis. .................................................................................................................. page 27 33. Entrapment of lipase in polymer of polyvinyl alcohol-boric acid for esterification in organic media .............. page 27 34. Boric acid for refractory candida glabrata vaginitis ........................................................................................... page 28 35. Boric acid for refractory Candida glabrata vaginitis. ......................................................................................... page 29 36. Candidiasis (vulvovaginal). ............................................................................................................................... page 29 37. Candidiasis (vulvovaginal) ................................................................................................................................ page 30 38. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis ........................................................................ page 31 39. Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis. ....................................................................... page 32 40. Study on physicochemical properties and pharmacodynamic action of recombinant uricase ........................... page 33 41. Phospholipase, proteinase and haemolytic activities of Candida albicans isolated from oral cavities of patients with type 2 diabetes mellitus ............................................................................................................................................ page 34 42. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis. ............................................................................................................................................................... page 35 43. Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis ................................................................................................................................................................ page 36 44. Local treatment of vulvovaginal candidosis: General and practical considerations .......................................... page 37 45. Recalcitrant Trichomonas Vaginalis Infections Successfully Treated With Vaginal Acidification ................... page 40 46. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification ........................ page 41 47. Recalcitrant Trichomonas vaginalis infections successfully treated with vaginal acidification. ....................... page 42 48. Biotypes, genotypes and ketoconazole susceptibility of Candida albicans isolates from a group of Thai AIDS patients ....................................................................................................................................................................
Recommended publications
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Vaginal Yeast Infections Yeast Are Caused Byinfection an Overgrowth of Yeast in the Vagina

    Vaginal Yeast Infections Yeast Are Caused Byinfection an Overgrowth of Yeast in the Vagina

    •Vaginal Yeast infections Yeast are caused byInfection an overgrowth of yeast in the vagina. • Yeast infections can be treated with over-the-counter medications. • Many yeast infections can be treated without seeing a medical provider. Symptoms: • Vaginal Itching, burning, swelling • Vaginal discharge (thick white vaginal discharge that looks like cottage cheese and does not have a bad smell) • May have pain during sex • May be worse the week before your period Self-care measures: • Use an over-the-counter medication for vaginal yeast infections. These antifungal medications should contain butoconazole, clotrimazole, miconazole, or tioconazole and should be used for 3-7 days. Follow directions on medication insert. Note: Over-the-counter medications are available at the University Health Center Pharmacy (first floor of Student Success Center), local pharmacies, grocery stores and superstores (examples - Walmart or Target). • Change tampons, pads and panty liners often • Do wear underwear with a cotton crotch • Apply a cool compress to labia for comfort • Do not douche or use vaginal sprays • Do not wear tight underwear and do not wear underwear to sleep • Avoid hot tubs Limit spread to others: • It is possible to spread yeast infections to your partner(s) during vaginal, oral or anal sex. • If your partner is a male, the risk is low. Some men get an itchy rash on their penis. • If this happens have your partner see a medical provider. • If your partner is a female, you may spread the yeast infection to her. • She should be treated if she
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr

    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
  • Crux 93 MAY-JUN 2019.Cdr

    Crux 93 MAY-JUN 2019.Cdr

    VOLUME - XVI ISSUE - XCIII MAY/JUN 2019 Vaginitis, also known as vulvovaginitis, is inflammation of the vagina and vulva. Symptoms may include itching, burning, pain, discharge, and a bad smell. Certain types of vaginitis may result in complications during pregnancy. 1 Editorial The three main causes are infections, specifically bacterial vaginosis, vaginal yeast Disease infection, and trichomoniasis. Other causes include allergies to substances such as 2 spermicides or soaps or as a result of low estrogen levels during breast-feeding or Diagnosis after menopause. More than one cause may exist at a time. The common causes 8 Interpretation vary by age. Diagnosis generally include examination, measuring the pH, and culturing the discharge. Other causes of symptoms such as inflammation of the cervix, pelvic Troubleshooting 13 inflammatory disease, cancer, foreign bodies, and skin conditions should be ruled out. 15 Bouquet Treatment depends on the underlying cause. Infections should be treated. Sitz baths may help with symptoms. Soaps and feminine hygiene products such as 16 Tulip News sprays should not be used. About a third of women have vaginitis at some point in time. Women of reproductive age are most often affected. The “DISEASE DIAGNOSIS” segment delves deep into the various CLINOCODIAGNOSTIC aspects of Vaginitis. “INTERPRETATION” portion highlights a very common disorder termed as BACTERIAL VAGINOSIS. Though not dangerous in itself, it predisposes to other sinister STDs. What we are discussing in “INTERPRETATION” is all about bacteria and the Primary investigation when t dealing with bacteria is GRAM's STAIN. Hence “TROUBLESHOOTING” part of this issue discusses GRAM's STAIN. What can possibly go wrong, how to identify and thereafter rectify the issues involved.
  • See the Document

    See the Document

    IN THE NAME OF GOD IRAN NAMA RAILWAY TOURISM GUIDE OF IRAN List of Content Preamble ....................................................................... 6 History ............................................................................. 7 Tehran Station ................................................................ 8 Tehran - Mashhad Route .............................................. 12 IRAN NRAILWAYAMA TOURISM GUIDE OF IRAN Tehran - Jolfa Route ..................................................... 32 Collection and Edition: Public Relations (RAI) Tourism Content Collection: Abdollah Abbaszadeh Design and Graphics: Reza Hozzar Moghaddam Photos: Siamak Iman Pour, Benyamin Tehran - Bandarabbas Route 48 Khodadadi, Hatef Homaei, Saeed Mahmoodi Aznaveh, javad Najaf ...................................... Alizadeh, Caspian Makak, Ocean Zakarian, Davood Vakilzadeh, Arash Simaei, Abbas Jafari, Mohammadreza Baharnaz, Homayoun Amir yeganeh, Kianush Jafari Producer: Public Relations (RAI) Tehran - Goragn Route 64 Translation: Seyed Ebrahim Fazli Zenooz - ................................................ International Affairs Bureau (RAI) Address: Public Relations, Central Building of Railways, Africa Blvd., Argentina Sq., Tehran- Iran. www.rai.ir Tehran - Shiraz Route................................................... 80 First Edition January 2016 All rights reserved. Tehran - Khorramshahr Route .................................... 96 Tehran - Kerman Route .............................................114 Islamic Republic of Iran The Railways
  • Guidelines for the Management of Sexually Transmitted Infections

    Guidelines for the Management of Sexually Transmitted Infections

    GUIDELINES FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS 3. TREATMENT OF SPECIFIC INFECTIONS 3.1. GONOCOCCAL INFECTIONS A large proportion of gonococcal isolates worldwide are now resistant to penicillins, tetracyclines, and other older antimicrobial agents, which can therefore no longer be 32 recommended for the treatment of gonorrhoea. TREATMENT OF SPECIFIC INFECTIONS SPECIFIC OF TREATMENT It is important to monitor local in vitro susceptibility,as well as the clinical efficacy of recommended regimens. Note In general it is recommended that concurrent anti-chlamydia therapy be given to all patients with gonorrhoea, as described in the section on chlamydia infections, since dual infection is common.This does not apply to patients in whom a specific diagnosis of C. trachomatis has been excluded by a laboratory test. UNCOMPLICATED ANOGENITAL INFECTION Recommended regimens I ciprofloxacin, 500 mg orally,as a single dose OR I azithromycin, 2 g orally,as a single dose OR I ceftriaxone, 125 mg by intramuscular injection, as a single dose OR I cefixime, 400 mg orally,as a single dose OR I spectinomycin, 2 g by intramuscular injection, as a single dose. Note I Ciprofloxacin is contraindicated in pregnancy.The manufacturer does not recommend it for use in children and adolescents. GUIDELINES FOR THE MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS I There is accumulating evidence that the cure rate of Azithromycin for gonococcal infections is best achieved by a 2-gram single dose regime.The 1-gram dose provides protracted sub-therapeutic levels which may precipitate the emergence of resistance. There are variations in the anti-gonococcal activity of individual quinolones, and it is important to use only the most active.
  • Sexually Transmitted Infections Treatment Guidelines, 2021

    Sexually Transmitted Infections Treatment Guidelines, 2021

    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 70 / No. 4 July 23, 2021 Sexually Transmitted Infections Treatment Guidelines, 2021 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS Introduction ............................................................................................................1 Methods ....................................................................................................................1 Clinical Prevention Guidance ............................................................................2 STI Detection Among Special Populations ............................................... 11 HIV Infection ......................................................................................................... 24 Diseases Characterized by Genital, Anal, or Perianal Ulcers ............... 27 Syphilis ................................................................................................................... 39 Management of Persons Who Have a History of Penicillin Allergy .. 56 Diseases Characterized by Urethritis and Cervicitis ............................... 60 Chlamydial Infections ....................................................................................... 65 Gonococcal Infections ...................................................................................... 71 Mycoplasma genitalium .................................................................................... 80 Diseases Characterized
  • Use of Nifuratel to Treat Infections Caused by Atopobium Species

    Use of Nifuratel to Treat Infections Caused by Atopobium Species

    (19) & (11) EP 2 243 482 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.10.2010 Bulletin 2010/43 A61K 31/422 (2006.01) A61P 15/02 (2006.01) A61P 31/04 (2006.01) A61P 13/02 (2006.01) (2006.01) (21) Application number: 09158221.3 A61P 15/00 (22) Date of filing: 20.04.2009 (84) Designated Contracting States: (72) Inventor: Mailland, Federico AT BE BG CH CY CZ DE DK EE ES FI FR GB GR CH-6900 Lugano (CH) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR (74) Representative: Pistolesi, Roberto et al Designated Extension States: Dragotti & Associati Srl AL BA RS Via Marina 6 20121 Milano (IT) (71) Applicant: Polichem SA 1526 Luxembourg (LU) (54) Use of nifuratel to treat infections caused by atopobium species (57) The present invention is directed to the use of genitalia in both sexes, as well as bacterial vaginosis, or nifuratel, or a physiologically acceptable salt thereof, to mixed vaginal infections in women, when one or more treat infections caused by Atopobium species. The in- species of the genus Atopobium are among the causative vention is further directed to the use of nifuratel to treat pathogens of those infections. bacteriuria, urinary tract infections, infections of external EP 2 243 482 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 243 482 A1 Description [0001] The present invention relates to the use of nifuratel, or a physiologically acceptable salt thereof, to treat infections caused by Atopobium species.
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set

    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
  • Mayors for Peace Member Cities 2021/10/01 平和首長会議 加盟都市リスト

    Mayors for Peace Member Cities 2021/10/01 平和首長会議 加盟都市リスト

    Mayors for Peace Member Cities 2021/10/01 平和首長会議 加盟都市リスト ● Asia 4 Bangladesh 7 China アジア バングラデシュ 中国 1 Afghanistan 9 Khulna 6 Hangzhou アフガニスタン クルナ 杭州（ハンチォウ） 1 Herat 10 Kotwalipara 7 Wuhan ヘラート コタリパラ 武漢（ウハン） 2 Kabul 11 Meherpur 8 Cyprus カブール メヘルプール キプロス 3 Nili 12 Moulvibazar 1 Aglantzia ニリ モウロビバザール アグランツィア 2 Armenia 13 Narayanganj 2 Ammochostos (Famagusta) アルメニア ナラヤンガンジ アモコストス（ファマグスタ） 1 Yerevan 14 Narsingdi 3 Kyrenia エレバン ナールシンジ キレニア 3 Azerbaijan 15 Noapara 4 Kythrea アゼルバイジャン ノアパラ キシレア 1 Agdam 16 Patuakhali 5 Morphou アグダム（県） パトゥアカリ モルフー 2 Fuzuli 17 Rajshahi 9 Georgia フュズリ（県） ラージシャヒ ジョージア 3 Gubadli 18 Rangpur 1 Kutaisi クバドリ（県） ラングプール クタイシ 4 Jabrail Region 19 Swarupkati 2 Tbilisi ジャブライル（県） サルプカティ トビリシ 5 Kalbajar 20 Sylhet 10 India カルバジャル（県） シルヘット インド 6 Khocali 21 Tangail 1 Ahmedabad ホジャリ（県） タンガイル アーメダバード 7 Khojavend 22 Tongi 2 Bhopal ホジャヴェンド（県） トンギ ボパール 8 Lachin 5 Bhutan 3 Chandernagore ラチン（県） ブータン チャンダルナゴール 9 Shusha Region 1 Thimphu 4 Chandigarh シュシャ（県） ティンプー チャンディーガル 10 Zangilan Region 6 Cambodia 5 Chennai ザンギラン（県） カンボジア チェンナイ 4 Bangladesh 1 Ba Phnom 6 Cochin バングラデシュ バプノム コーチ（コーチン） 1 Bera 2 Phnom Penh 7 Delhi ベラ プノンペン デリー 2 Chapai Nawabganj 3 Siem Reap Province 8 Imphal チャパイ・ナワブガンジ シェムリアップ州 インパール 3 Chittagong 7 China 9 Kolkata チッタゴン 中国 コルカタ 4 Comilla 1 Beijing 10 Lucknow コミラ 北京（ペイチン） ラクノウ 5 Cox's Bazar 2 Chengdu 11 Mallappuzhassery コックスバザール 成都（チォントゥ） マラパザーサリー 6 Dhaka 3 Chongqing 12 Meerut ダッカ 重慶（チョンチン） メーラト 7 Gazipur 4 Dalian 13 Mumbai (Bombay) ガジプール 大連（タァリィェン） ムンバイ（旧ボンベイ） 8 Gopalpur 5 Fuzhou 14 Nagpur ゴパルプール 福州（フゥチォウ） ナーグプル 1/108 Pages
  • PDF Library/Candidiasis.Pdf 7 Sexually Transmitted Diseases Treatment Guidelines, 2010

    PDF Library/Candidiasis.Pdf 7 Sexually Transmitted Diseases Treatment Guidelines, 2010

    COMMISSION DE LA TRANSPARENCE Avis 2 octobre 2013 FLUCONAZOLE MAJORELLE 150 mg, gélule B/1 (34009 395 173 0 8) Laboratoire MAJORELLE DCI fluconazole Code ATC (2012) J02AC01 (Antimycosiques à usage systémique) Motif de l’examen Inscription Liste(s) Sécurité Sociale (CSS L.162-17) concernée(s) Collectivités (CSP L.5123-2) Indication(s) « Traitement des Candidoses vaginales et périnéales aiguës et concernée(s) récidivantes » HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 1/12 Avis 1 modifié le 28 novembre 2014 SMR SMR modéré ASMR ASMR de niveau V Place dans la Le traitement des candidoses vaginales et périnéales aiguës et récidivantes , stratégie peut être local ou systémique. Dans le cas d’un traitement systémique, il thérapeutique s’agit d’un traitement en dose unique. HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique 2/12 Avis 1 modifié le 28 novembre 2014 01 INFORMATIONS ADMINISTRATIVES ET REGLEMENTAIRES AMM 24/07/2009 (procédure nationale) Conditions de prescription et de Liste I délivrance / statut particulier 2012 J Anti-infectieux généraux à usage systémique J02 Antimycosiques à usage systémique Classification ATC J02A Antimycosiques à usage systémique J02AC Dérivés triazolés J02AC01 Fluconazole 02 CONTEXTE Il s’agit d’une demande d’inscription de la spécialité FLUCONAZOLE MAJORELLE 150 mg en gélule, sur la liste des spécialités remboursables aux assurés sociaux et sur la liste des médicaments agrées à l’usage des collectivités. FLUCONAZOLE MAJORELLE 150 mg est un générique de la spécialité princeps FLUCONAZOLE PFIZER 150 mg. Il existe deux autres spécialités génériques, BEAGYNE 150 mg et FLUCONAZOLE SANDOZ 150 mg.
  • Systematics, Phylogeny and Biogeography of Cousinia (Asteraceae)

    Systematics, Phylogeny and Biogeography of Cousinia (Asteraceae)

    SYSTEMATICS, PHYLOGENY AND BIOGEOGRAPHY OF COUSINIA (ASTERACEAE) Dissertation Zur Erlangung des Grades Doktor der Naturwissenschaften am Fachbereich Biologie der Johannes Gutenberg‐Universität Mainz Iraj Mehregan geb. in Gachsaran, Iran Mainz, 2008 Dekan: 1. Berichterstatter: 2. Berichterstatter: Tag der mündlichen Prüfung: 10. 07. 2008 II Kapitel 2 (chapter 2) dieser Arbeit ist im Druck bei “Taxon“: López‐Vinyallonga, S., Mehregan, I.*, Garcia‐Jacas, N., Tscherneva, O., Susanna, A. & Kadereit, J. W.*: Phylogeny and evolution of the Arctium‐Cousinia complex (Compositae, Cardueae‐Carduinae). * Von den Autoren Mehregan, I und Kadereit, J. W.: Die Generation der ITS‐Sequenzen von 113 Taxa (Appendix 1), die Bayesische Analyse der ITS‐ und rpS4‐trnT‐trnL‐Sequenzen, das Rechnen der Molekularen Uhr sowie der Partition‐Hemogenity Test und die Analyse des Cousinioid Clade wurde in Rahmen dieser Dissertation ausgeführt. Das Manuskript wurde in Zusammenarbeit aller Autoren geschrieben. Kapitel 3 (chapter 3) diese Arbeit wird bei “Willdenowia” eingereicht: Mehregan, I. & Kadereit, J. W.: The role of hybridization in the evolution of Cousinia s.s. (Asteraceae). Kapitel 4 (chapter 4) dieser Arbeit ist im Druck bei “Willdenowia“: Mehregan, I. & Kadereit, J. W.: Taxonomic revision of Cousinia sect. Cynaroideae. III Contents SUMMARY............................................................................................................................................................................1 ZUSAMMENFASSUNG .....................................................................................................................................................2